Free Trial

Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Here's Why

Bicycle Therapeutics logo with Medical background

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report)'s stock price gapped up before the market opened on Friday . The stock had previously closed at $7.41, but opened at $7.72. Bicycle Therapeutics shares last traded at $7.43, with a volume of 49,233 shares.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BCYC shares. JMP Securities lowered their price target on Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating for the company in a report on Friday, May 2nd. Morgan Stanley set a $17.00 price objective on shares of Bicycle Therapeutics and gave the stock an "equal weight" rating in a report on Monday, May 5th. Barclays lowered their target price on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Needham & Company LLC restated a "buy" rating and issued a $29.00 price target on shares of Bicycle Therapeutics in a research report on Friday, May 2nd. Finally, Royal Bank Of Canada lowered their price objective on shares of Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $25.00.

Check Out Our Latest Analysis on BCYC

Bicycle Therapeutics Trading Down 2.6%

The company's 50-day moving average price is $8.20 and its two-hundred day moving average price is $10.78. The company has a market cap of $500.71 million, a P/E ratio of -2.30 and a beta of 1.46.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Bicycle Therapeutics had a negative return on equity of 25.54% and a negative net margin of 790.07%. The business had revenue of $9.98 million during the quarter, compared to analyst estimates of $8.67 million. Equities analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current year.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Barclays PLC increased its stake in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after purchasing an additional 2,345 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Bicycle Therapeutics by 879.5% in the first quarter. GAMMA Investing LLC now owns 8,982 shares of the company's stock worth $76,000 after purchasing an additional 8,065 shares in the last quarter. Exchange Traded Concepts LLC increased its position in Bicycle Therapeutics by 90.3% during the first quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock worth $108,000 after buying an additional 6,057 shares during the last quarter. Cerity Partners LLC bought a new position in Bicycle Therapeutics during the first quarter valued at about $113,000. Finally, Portland Investment Counsel Inc. acquired a new stake in shares of Bicycle Therapeutics in the first quarter worth about $127,000. Institutional investors and hedge funds own 86.15% of the company's stock.

About Bicycle Therapeutics

(Get Free Report)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

Further Reading

Should You Invest $1,000 in Bicycle Therapeutics Right Now?

Before you consider Bicycle Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.

While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines